Hungarian AI drug discovery company Turbine raised EUR 20 million (USD 21 million) in a Series A funding round co-led by Mercia and MSD Global Health Innovation (GHI) Fund—MSD is Merck & Co’s brand name outside the US and Canada. Other investors included Day One Capital, Accel, and Delin Ventures.
The proceeds will be used to fuel the advancement of its therapeutic programs—identified by its AI Platform “Simulated Cell”—targeting DNA damage repair, expand the team, and enter into new partnerships with pharmaceutical companies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.